Benzinga | Aug 5, 2021 05:34AM EDT

JP Morgan Upgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $87

JP Morgan analyst Anupam Rama upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Underweight to Neutral and lowers the price target from $92 to $87.